{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:45:55Z","timestamp":1791747955117,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Anusandhan National Research Foundation","doi-asserted-by":"publisher","award":["CRG\/2022\/002939"],"award-info":[{"award-number":["CRG\/2022\/002939"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["52\/29\/2020-Bio\/BMS"],"award-info":[{"award-number":["52\/29\/2020-Bio\/BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.clim.2026.110761","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:39:30Z","timestamp":1787931570000},"page":"110761","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["TIM-3 as a therapeutic target in anaplastic thyroid carcinoma: Preclinical and transcriptomic evidence supporting a new immunotherapy avenue"],"prefix":"10.1016","volume":"288","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7687-0027","authenticated-orcid":false,"given":"Monikongkona","family":"Boruah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyaz Ahmad","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Sikka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7037-4444","authenticated-orcid":false,"given":"Shipra","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2026.110761_bb0005","doi-asserted-by":"crossref","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","article-title":"Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Haddad","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.clim.2026.110761_bb0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.clim.2026.110761_bb0015","article-title":"Development of PD-1\/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung Cancer","volume":"5","author":"He","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clim.2026.110761_bb0020","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.clim.2026.110761_bb0025","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12022-024-09832-1","article-title":"Unravelling the reasons behind limited response to anti-PD therapy in ATC: a comprehensive evaluation of tumor-infiltrating immune cells and checkpoints","volume":"35","author":"Boruah","year":"2024","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.clim.2026.110761_bb0030","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.clim.2026.110761_bb0035","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1007\/s00262-023-03516-1","article-title":"TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors","volume":"72","author":"Sauer","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.clim.2026.110761_bb0040","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2026.110761_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1320481","article-title":"Characterization of CD4+ and CD8+ T cells responses in the mixed lymphocyte reaction by flow cytometry and single cell RNA sequencing","volume":"14","author":"Mangelinck","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110761_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.931316","article-title":"CTLA-4 silencing in dendritic cells loaded with colorectal cancer cell lysate improves autologous T cell responses in vitro","volume":"13","author":"Ghorbaninezhad","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110761_bb0055","series-title":"Immune Checkp. Blockade","first-page":"133","article-title":"Assessment of antitumor T-cell responses by flow cytometry after coculture of tumor cells with autologous tumor-infiltrating lymphocytes","volume":"1913","author":"Melief","year":"2019"},{"key":"10.1016\/j.clim.2026.110761_bb0060","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000497","article-title":"New emerging targets in cancer immunotherapy: the role of TIM3","volume":"4","author":"Friedlaender","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.clim.2026.110761_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194821","article-title":"Secreted factors by anaplastic thyroid cancer cells induce tumor-promoting M2-like macrophage polarization through a TIM3-dependent mechanism","volume":"13","author":"Stempin","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.clim.2026.110761_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/biology11111609","article-title":"TIM3 expression in anaplastic thyroid cancer-infiltrating macrophages: an emerging immunotherapeutic target","volume":"11","author":"Palacios","year":"2022","journal-title":"Biology"},{"key":"10.1016\/j.clim.2026.110761_bb0075","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ni988","article-title":"Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance","volume":"4","author":"Sabatos","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.clim.2026.110761_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107458","article-title":"The role of Tim-3 blockade in the tumor immune microenvironment beyond T cells","volume":"209","author":"Zhang","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.clim.2026.110761_bb0085","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-25-0806","article-title":"Combined targeting of PD-1 and TIM-3 in patients with locally advanced or metastatic non-small cell lung cancer: AMBER part 2B","volume":"31","author":"Davar","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2026.110761_bb0090","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1158\/1078-0432.CCR-25-0884","article-title":"Combined targeting of PD-1 and TIM-3 in patients with locally advanced or metastatic melanoma: AMBER cohorts 1c, 1e, and 2A","volume":"31","author":"Davar","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2026.110761_bb0095","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.intimp.2018.09.016","article-title":"Dysfunction of natural killer cells mediated by PD-1 and Tim-3 pathway in anaplastic thyroid cancer","volume":"64","author":"Yin","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.clim.2026.110761_bb0100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s43556-025-00267-6","article-title":"TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives","volume":"6","author":"Yan","year":"2025","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.clim.2026.110761_bb0105","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1128\/MMBR.00024-13","article-title":"Mx proteins: antiviral gatekeepers that restrain the uninvited","volume":"77","author":"Verhelst","year":"2013","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.clim.2026.110761_bb0110","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20212403","article-title":"Clinical significance and biological functions of chemokine CXCL3 in head and neck squamous cell carcinoma","volume":"41","author":"Guan","year":"2021","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.clim.2026.110761_bb0115","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41588-020-00753-3","article-title":"The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer","volume":"53","author":"Najumudeen","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.clim.2026.110761_bb0120","doi-asserted-by":"crossref","first-page":"10718","DOI":"10.1038\/s41598-019-47218-0","article-title":"E2F1 drives breast Cancer metastasis by regulating the target gene FGF13 and altering cell migration","volume":"9","author":"Hollern","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clim.2026.110761_bb0125","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.omto.2021.12.026","article-title":"ENO1 and Cancer","volume":"24","author":"Huang","year":"2022","journal-title":"Mol. Ther. Oncolyt."},{"key":"10.1016\/j.clim.2026.110761_bb0130","article-title":"ENO1 promotes PDAC progression by inhibiting CD8+ T cell infiltration through upregulating PD-L1 expression via HIF-1\u03b1 signaling","volume":"52","author":"Tulamaiti","year":"2025","journal-title":"Transl. Oncol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626000999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626000999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T18:49:40Z","timestamp":1791744580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661626000999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":26,"alternative-id":["S1521661626000999"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2026.110761","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TIM-3 as a therapeutic target in anaplastic thyroid carcinoma: Preclinical and transcriptomic evidence supporting a new immunotherapy avenue","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2026.110761","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110761"}}